Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Bristol-Myers Squibb Company (BMY) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for BMY model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are
accounted for in this model in the form of the historical data coincided with outbreaks and other
global events in the past used to train ML prediction model for BMY.
Model is being retrained on a daily basis.
| Float | 1631M |
| P/E | 16.56 |
| Shares Outstanding | 1635M |
| % Held by Insiders | 0.23% |
| % Held by Institutions | 71.69% |
| EPS (last reported FY) | $3.01 |
| EPS (last reported Q) | $0.94 |
| EPS, estimated (last reported Q) | $0.85 |
| Total revenues | $21 B |
| Net income | $1 B |